資源描述：
《鹽酸吉西他濱聯(lián)合順鉑對(duì)非小細(xì)胞肺癌外周血調(diào)節(jié)性T細(xì)胞水平影響的研究.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫(kù)。
1、中國(guó)當(dāng)代醫(yī)藥2014年6月第21卷第17期·藥物與臨床·鹽酸吉西他濱聯(lián)合順鉑對(duì)非小細(xì)胞肺癌外周血調(diào)節(jié)性T細(xì)胞水平影響的研究彭東旭方曉娟杜均祥梁翠微潘瑩1．廣東省珠海市人民醫(yī)院腫瘤科，廣東珠海519000；2．中山大學(xué)附屬第五醫(yī)院CCU，廣東珠海519000【摘要】目的探討鹽酸吉西他濱聯(lián)合順鉑對(duì)非小細(xì)胞肺癌外周血調(diào)節(jié)性T細(xì)胞水平的影響，從而為相關(guān)臨床研究提供依據(jù)和參考。方法本次研究人選的病例均為本院2009年1月～2012年12月收治的非小細(xì)胞肺癌患者5O例(非小細(xì)胞癌組)，同期健康體檢者34例(健康對(duì)照組)，觀察記錄全部研究對(duì)象以及患者實(shí)施
2、治療前后CD4+CDFoxp+／CD4+水平，并對(duì)相關(guān)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)分析。結(jié)果健康對(duì)照組的CDCD+Foxp3+／CD4+顯著低于非小細(xì)胞癌組。且組間比較差異有統(tǒng)計(jì)學(xué)意義；不同類(lèi)型的非小細(xì)胞癌患者實(shí)施治療后，較治療前該項(xiàng)指標(biāo)水平得到顯著降低．且治療前后比較差異均有統(tǒng)計(jì)學(xué)意義(P<0．05)。結(jié)論鹽酸吉西他濱聯(lián)合順鉑的治療方案可以顯著調(diào)節(jié)非小細(xì)胞肺癌患者的外周血調(diào)節(jié)性T細(xì)胞水平，可有效調(diào)節(jié)患者的腫瘤免疫耐受，從而顯著改善患者的免疫功能，是臨床治療非小細(xì)胞肺癌的理想選擇。【關(guān)鍵詞】鹽酸吉西他濱聯(lián)合順鉑；非小細(xì)胞肺癌；外周血調(diào)節(jié)性T細(xì)胞【中圖分類(lèi)
3、號(hào)】R734．2【文獻(xiàn)標(biāo)識(shí)碼】A[文章編號(hào)】1674-4721(2014)O6(b)一0O75—03Impactstudyofgemcitabinehydrochloridecombiningwithcis-platinumonlevelsofregulatoryTcellsinperipheralbloodinpatientswithnon-smallcelllungcancerPENGDong-xuFANGXiao-yuan。DUJun-xiangILIANGCui-weiPANvi,~d1．DepartmentofOneology，Z
4、huhaiPeopleSHospitalofGuangdongProvince，Zhuhai519000，China；2．CoronaryCareU-nit，theFifthAfiliatedHospital，SunYat-SenUniversity，Zhuhai519000，China[Abstract]ObjectiveTofurtherexploretheimpactofgemcitabinehydroehloridecombiningwithcis——platinumonlev·elsofregulatoryTcellsinperi
5、pheralbloodinpatientswithnon—smallcelllungcancer(NSCLC)aimingatprovidingbasisandreferenceforrelatedclinicalresearches．Methods50NSCLCpatientsadmittedintoourhospitalfromJanuary2009toDecember2012wereselected．Another34healthyparticipantsinthesameperiodwerechosenashealthycon—tr
6、olgroup．ClinicaldatafromallparticipantsandlevelsofCD4+CD2s+Foxp3+／CD4beforeandaftertherapywereobservedandrecorded，andtherelateddatawerecomparativelyanalyzed．ResultsWithregardtoCD4+CD~+Foxp3VCD4+，thelevelinthehealthycontrolgroupwaslowerthanthatintheNSCLCgroupwithastatistica
7、ldifference．Aftertreatment，levelsofCD4CD25Foxp3+／CD4indifferenttypesofNSCLCpatientsremarkablydecreasedincomparisonwiththosebeforetreatmentrespectively，whichalldisplayedstatisticaldiferences<0．05)．ConclusionTherapeuticregimenofgemc—itabinehydrochloridecombiningWithcis—plati
8、numcanremarkablyregulateregulatoryTcellsinperipheralbloodin．NSCLCpatientsandtumorimmuneto
